Recommendations: Agend a no. Recommendations. Institute. New Drugs Division /12-DC ArbekacinSulphate Injection 200mg/4ml
|
|
- Geoffrey Manning
- 6 years ago
- Views:
Transcription
1 : I approve the minutes of 32 nd SEC (Antimicrobial, Antiviral, Antiparasitic and Antifungal) held on at CDSCO HQ New Delhi and recommended the following: Agend New Drugs Division /12-DC ArbekacinSulphate Injection 200mg/4ml M/s. Alkem Fixed Dose Combination Division The firm did not turn up for presentation /2016-DC(Pt. Maneesh) Rifampicin IP+Isoniazid IP (450mg+225mg) Maneesh The firm presented the BE protocol for the FDC of Pyridoxine (vit B6) 10 mg with Rifampicin 450mg, Isoniazid 225mg, Pyrazinamide 1200 mg and Ethambutol Hcl 825mg Sachet with the Reference product Rimstar (3 tablets) of Sandoz Denmark (Each tab. containing Rifampicin 150mg, Isoniazid 75mg, Pyrazinamide 400mg and Ethambutol Hcl 275mg).The firm also informed that the BE data for the proposed 4 drug FDCs will be extrapolated to 2 drugs and 3 drugs FDCs. The Committee deliberated and recommended for conduct of proposed BE study. After the submission of BE report the proposal for Phase III Clinical trial will be considered as already recommended in the previous meeting held on Page 1 of 6
2 /2016-DC Daclatasvir+Sofosbuvir ( 60mg+400mg) /2000-DC(Pt.Cipla) Lopinavir+Ritonavir ( 40mg+10mg) M/s NATCO Pharma M/s. Cipla Ltd., Page 2 of 6 The firm presented the BE study data conducted for export purpose as recommended by the Committee in the previous meeting held on The committee reviewed and found the BE data satisfactory. Further the firm also requested for the CT waiver based on the recent circular issued by DCG(I) on The Committee did not recommended for the CT waiver as the proposed drug does not fall under the category of extreme urgency. The firm was directed by the Committee to conduct the acceptability and feasibility study in Indian pediatric population in its meeting held on However the firm expressed its inability to conduct such study. Further the firm also requested for the study waiver based on the recent circular issued by DCG(I) on The Committee opined that the above circular is not applicable for the proposed study and has insisted to do
3 /2009-DC(Pt. EM) DarunavirEthanolateeq.to Darunavir+Ritonavir IP (600mg+100mg) /2016-DC Each Combikit contains: Part A: two film coated tablets of darunavirethanolate eq. to Darunavir 600mg and Part B: two film coated tablets of Ritonavir IP100mg M/s. Emcure M/s. Emcure Page 3 of 6 the study as proposed in earlier meeting held on The Firm presented the Pharmacokinetic Interaction Study report before the Committee. The Committee recommended for the approval of manufacturing and marketing of FDC of Darunavir Ethanolate eq. to Darunavir + Ritonavir IP (600mg+100mg) for the indication for the treatment of Human immunodeficiency virus (HIV) infection in antiretroviral treatment experienced adult patients, such as those patients with HIV-1 strains resistant to more than one protease inhibitor and with other antiretroviral agents. The Firm presented the Pharmacokinetic Interaction Study report for FDC of Darunavir Ethanolate eq. to Darunavir + Ritonavir IP (600mg+100mg) before the Committee. The Committee recommended for the approval of manufacturing and marketing of proposed combikit of Part A: two film coated tablets of Darunavir Ethanolate eq. to Darunavir 600mg and Part B: two film
4 /2017-DC Part A: One film coated tablets of EmtricitabineIP+TenofovirDisoproxilFumara te IP & Part B: One Uncoated tablets of Nevirapine Extended release tablets (Nevirapine USP)(200mg+300mg & 400mg)Combikit Medical Devices M/s. Emcure coated tablets of Ritonavir IP 100mg Combikit for the indication for the treatment of Human immunodeficiency virus (HIV) infection in antiretroviral treatment experienced adult patients, such as those patients with HIV-1 strains resistant to more than one protease inhibitor and with other antiretroviral agents. The firm presented the proposal for the proposed combikit of Part A: One film coated tablets of Emtricitabine IP + Tenofovir Disoproxil Fumarate IP & Part B: One Uncoated tablets of Nevirapine Extended release tablets (Nevirapine USP) (200mg+300mg & 400mg). The committee after detailed deliberation did not recommend the proposed combikit as it will not provide any additional benefit. 8 4-MD/CT-105/2013-DC (Part-2) Application in Form 44 for permission to conduct Clinical Trial titled of product i.e., Hinglact Prime (Absorbable, antibacterialchlorhexidineacetate surgical PGA-PLAsuture) M/s. HLL Lifecare Ltd,Trivandrum , Kerala The firm could not present the adequate safety and efficacy data of the product. However the firm presented protocol for conducting clinical trial in India. The committee observed that the protocol has many limitations/inadequacy Page 4 of 6
5 . a) Sample size not calculated scientifically. b) Trial sites selected are inappropriate (small nursing homes) and without Institutional Ethics Committee. c) Inclusion criteria were not defined. d) The study methodology lacks clarity. Hence,the protocol in the present form is not acceptable. Page 5 of 6
6 S.No SEC Experts Name & Designation 1. Dr.Archna Thakur, Dir. Prof. Department of Microbiology, G. B Pant Hospital, New Delhi. Signature 2. Dr. B. Gupta Prof & Head Dept of Medicine, NDMC Medical college & Hindu Rao Hospital, New Delhi 3. Dr.Subhash C. Parija, Sr. Prof & HOD, Microbiology, JIPMER, Puducherry 4. Dr.Varsha Gupta, Prof. Department of Microbiology, Govt. medical college and Hospital (GMCH), Chandigarh 5. Dr.Amita Jain, Prof. Department of Microbiology, KGMU, Lucknow 6. Dr. C.D. Tripathi, Department of Pharmacology VMMC &Safdarjung Hospital, New Delhi 7. DrPratipKundu, MD Professor of Microbiology & Medical Superintendent cum Vice Principal, School of Tropical Medicine ChittaRanjan Avenue Kolkata 8. Dr. AbhishekAgrawal (Associate Professor) Dept. of Medicine SMS Medical College, Jaipur Page 6 of 6
M/s. Hetero Labs Ltd.
:- The 1 st SEC (Gastroenterology&Hepatology) meeting deliberated the proposals on 06.01.2017 and recommended the following:- Agenda New Drugs Division Proposal 1 12-54/16-DC Sofosbuvir and Velpatasvir
More informationRecommendations of thesec (Dermatology & Allergy) made in its 23 rd meeting held on at CDSCO HQ New Delhi: New Drugs Division
Recommetions of thesec (Dermatology & Allergy) made in its 23 rd meeting held on 11.05.2017 at CDSCO HQ New Delhi: File /Drug Name Recommetions New Drugs Division 1 12-28/15-DC (Pt-B) Apremilast 10/20/30
More information14 th SEC- Gastroenterology& Hepatology held on at CDSCO (HQ), FDA Bhawan, Kotla road, NewDelhi
14 th SEC- Gastroenterology& Hepatology held on 27-08-2015 at CDSCO (HQ), FDA Bhawan, Kotla road, NewDelhi 110 002 Recommendation:- The 14 th SEC ( Gastroenterology& Hepatology) meeting deliberated the
More informationThe NDAC (Antimicrobial, Antiparasitic, Antifungal & Antiviral) deliberated the proposals on and recommended the following:-
Recommendation:- The NDAC (Antimicrobial, Antiparasitic, Antifungal & Antiviral) deliberated the proposals on 23.08.2013 and recommended the following:- Agenda no. Drug Recommendations 1 2 Raltegravir,
More information3. Dr.Rajutitus Chacko, Prof. & Head, Dept. of Medical Oncology, CMC, Vellore.
MINUTES OF THE 6 th MEETING OF TECHNICAL COMMITTEE HELD ON 25-07-2013 UNDER CHAIRMANSHIP OF DGHS FOR SUPERVISING CLINICAL TRIALS ON NEW CHEMICAL ENTITIES IN THE LIGHT OF DIRECTIONS OF THE HON BLE SUPREME
More information10 th SEC- (Reproductive & Urology)meetingheld on at CDSCO (HQ), FDA Bhawan, Kotla road, New Delhi PROGRAMME SCHEDULE
10 th SEC- (Reproductive & Urology)meetingheld on 16-01-2015 at CDSCO (HQ), FDA Bhawan, Kotla road, New Delhi 110 002 PROGRAMME SCHEDULE Recommendation:- The 10 th SEC (Reproductive and Urology) meeting
More informationSubsequent New Drugs Division. M/s.Troikaa. M/s. Olive Healthcare. Biological Division. M/s. Wockhardt Ltd. Global Clinical Trial Division
: The34 th SEC (Endocrinology & Metabolism) meeting held on 25.04.2017 at CDSCO HQ New Delhi and recommended the following: Age Subsequent New Drugs Division 1 12-146/2016-DC (Pt- Zim-Snd) Vitamin D3 (Cholecalciferol)
More informationName of firm/applicant. Torrent Pharmaceuticals. Glenmark Pharmaceuticals. M/s. Torrent Pharmaceutical. Torrent Pharmaceuticals
Recommendation:- The 14 Th SEC (Cardiovascular & Renal) deliberated the proposals on 21.08.2014 and recommended the following:- Agenda no. File no Name of firm/applicant Recommendations 1. 04-228/06-D(pt
More informationRecommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on and recommended the following:-
Recommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on 05.11.2014 and recommended the following:- Agend a No. File No. 1. File No.: 12-75/13-DC Afatinib film coated tablet
More information1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016
To support national and global efforts to increase access to and the affordability of HIV/AIDS-related care and treatment together with UNICEF, UNAIDS and UNITAID, invite applicants for selected pharmaceutical
More informationFile no./drug Name Name of firm/ Institute Recommendations. New Drugs Division
Recommendations: I approve the minutes of 52 nd SEC (Oncology & hematology) held on 13.04.2017 at CDSCO HQ New Delhi and recommended the following: Agenda 1 12-63/16-DC Ferric Pyrophosphate citrate solution
More informationThe legally binding text is the original French version. Opinion 28 May J05AE10 (protease inhibitor class of antiretrovirals)
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 28 May 2014 PREZISTA 400 mg, film-coated tablet B/60 (CIP: 34009 393 138 3 2) PREZISTA 800 mg, film-coated tablet
More informationEuropean Medicines Agency decision
EMA/785816/2015 European Medicines Agency decision P/0294/2015 of 3 December 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for
More informationInvitation to Manufacturers 16 August 2017
Invitation to Manufacturers 16 August 2017 Manufacturers of Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial medicines Are Invited to Submit An Expression of Interest
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More information1. RECOMMENDATIONS OF THE NDAC (GASTROENTEROLOGY & HEPATOLOGY) HELD ON :-
1. RECOMMENDATIONS OF THE NDAC (GASTROENTEROLOGY & HEPATOLOGY) HELD ON 02.04.2012:- The NDAC (Gastroenterology & Hepatology) deliberated the proposals on 02.04.2012 and recommended the following:- AGENDA
More informationSubject: Consolidated list of all cases of price fixation of new drugs received from various companies under para 5 of DPCO 2013
Subject: Consolidated list of all cases of price fixation of new drugs received from various companies under para 5 of DPCO 2013 Sl. No. F.No. Name of the Company/ Formulation Date of receipt of application
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 25.04.2017 BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ALEMBIC PHARMACEUTICALS 2. M/S. ALEMBIC PHARMACEUTICALS 3. M/S. ALEMBIC PHARMACEUTICALS 4. M/S. EMCURE PHARMACEUTICALS
More informationSCIENTIFIC DISCUSSION. Darunavir
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationSCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary, which are included in parts
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
More informationEvidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February For public consultation
Evidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February 2016 - NHS England Evidence Review: Comparison of tenofovir alafenamide and tenofovir disoproxil fumarate.
More informationAWMSG Secretariat Assessment Report Advice no Darunavir (Prezista
AWMSG Secretariat Assessment Report Advice no. 0311 Darunavir (Prezista ) for the treatment of HIV-1 infection in treatment-experienced children and adolescents This assessment report is based on evidence
More informationARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting
ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions
More informationSupplier/ Manufacturer(s) Unit III, Survey No 51, Plot No IDA, Jeedimetla, Hyderabad, Telangana, Hetero labs limited
LIST OF DELISTED PRODUCTS Not eligible for procurement with the Global Fund resources 06th of April 2018 Delisted Mar-18 Ritonavir (RTV) 0 mg Tablet Unit Survey No 51, Plot No 22-1 IDA, Jeedimetla, Hyderabad,
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 14.03.2016 IMPORT S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. TABLETS (INDIA) LIMITED 5973 APPROVAL 2. TABLETS (INDIA) LIMITED 5974 APPROVAL 3. CLARIS OTSUKA PRIVATE LIMITED 7373 APPROVAL
More informationHIV and FDC aspects of two guidelines. Filip Josephson
HIV and FDC aspects of two guidelines Filip Josephson Status Ongoing process Updated draft guideline for HIV drug development available for public consultation on EMA website since 2013 Presently under
More informationORDER. Table. Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Teneligliptin Hydrobromide + Metformin HCL (SR) Tablet
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of s National Pricing Authority ORDER New
More informationReverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review
pissn 2349-2910 eissn 2395-0684 REVIEW Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review Dinesh Bure, Department
More informationSCIENTIFIC DISCUSSION. Lopinavir and Ritonavir 200 mg/50 mg Tablets * Name of the Finished Pharmaceutical Product:
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
More information5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and
5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs
More informationDarunavir STADA 400, 600 and 800 mg film-coated tablets , Version 1.1 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Darunavir STADA 400, 600 and 800 mg film-coated tablets 7.9.2016, Version 1.1 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Human
More informationSummary of the risk management plan (RMP) for Rezolsta (darunavir / cobicistat)
EMA/608280/2014 Summary of the risk management plan (RMP) for Rezolsta (darunavir / cobicistat) This is a summary of the risk management plan (RMP) for Rezolsta, which details the measures to be taken
More informationScottish Medicines Consortium
Scottish Medicines Consortium darunavir 300mg tablets (Prezista ) No. (378/07) Tibotec (a division of Janssen-Cilag Ltd) 4 May 2007 The Scottish Medicines Consortium has completed its assessment of the
More informationClinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents Reference: NHS England F03/P/b NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationSupplementary Data. Supplementary Table S2. Antiretroviral Therapies Taken with Ledipasvir/Sofosbuvir
Supplementary Data Statistical Analysis Due to the limited number of patients with acute kidney injury and concern for model overfitting, covariates included in multivariable logistic regression analyses
More informationZepatier. (elbasvir, grazoprevir) New Product Slideshow
Zepatier (elbasvir, grazoprevir) New Product Slideshow Introduction Brand name: Zepatier Generic name: Elbasvir, grazoprevir Pharmacological class: HCV NS5A inhibitor + HCV NS3/4A protease inhibitor Strength
More informationSCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationClinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages) Reference: NHS England F03/P/b
Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages) Reference: NHS England F03/P/b NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Rifampicin/Isoniazid 150mg/75mg filmcoated Tablets Svizera
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 14.12.2015 LVP DIVISION S. COMPANY NAME FTS /DIARY STATUS 01 M/S. AXA PARENTERALS LTD., ROORKEE 60262 APPROVAL 02 M/S. UNIJULES LIFE SCIENCES LTD., NAGPUR 61147 APPROVAL 03 M/S. INNVOL MEDICAL
More informationHIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
More informationPractical Scenarios Calculating doses for newborns. Karen Buckberry
Practical Scenarios Calculating doses for newborns Karen Buckberry Real Life Midwife phones you HIV+ mother in labour Needs you to tell Dr what meds to prescribe for baby What info do you need? Info needed
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationNPPA has fixed/revised ceiling prices/retail prices of 22 formulations under Drugs (Prices Control) Order,
What s New 12.06.2018 NPPA has fixed/revised ceiling prices/retail prices of 22 formulations under Drugs (Prices Control) Order, 2013 NPPA has fixed/revised ceiling prices/retail prices of 22 formulations
More informationPriority essential medicines: identifying products. Dr Suzanne Hill September 2010
Priority essential medicines: identifying products Dr Suzanne Hill September 2010 The problem looks like this Robertson, Forte, Trapsida & Hill. Bull WHO 2009 Robertson, Forte, Trapsida & Hill. Bull WHO
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 11.04.2017 BIOLOGICAL DIVISION NAME OF COMPANY DY. NO. STATUS M/S ZUVENTUS HEALTHCARE LTD 6981 APPROVAL M/S TECHINVENTION LIFE SCIENCES 1208 CLARIFICATION M/S CADILA PHARMACEUTICALS LTD
More informationWHOPAR. SCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationUpdate on progress of MPP sublicensees
Update on progress of MPP sublicensees Medicines Patent Pool SEPTEMBER 2018 SUMMARY This presentation showcases the progress made by MPP licensees (generic pharmaceutical companies) To date, MPP has signed
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationGlobal College of Pharmacy, Kahnpur Khui, Tehsil Anandpur Sahib, Distt.- Ropar, Punjab, India
IJPSR (2012), Vol. 3, Issue 09 (Research Article) Received on 19 May, 2012; received in revised form 25 June, 2012; accepted 27 August, 2012 IN-VITRO EVALUATION OF TWO MARKETED BRANDS OF PARACETAMOL TABLETS
More informationSummary of treatment benefits
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Human immunodeficiency virus (HIV) attacks the cells of the immune system, the body's natural defense against germs and other
More informationSCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More information1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017
To support national and global efforts to increase access to and the affordability of care and treatment of HIV/AIDS, hepatitis B and C, tuberculosis, malaria, neglected tropical diseases, influenza, diarrhoea
More informationThe Medicines Patent Pool: An Update. June 2012 Geneva, Switzerland
The Medicines Patent Pool: An Update June 2012 Geneva, Switzerland The Medicines Patent Pool Royalties Licensor Licensor Patents Generics versions of existing compounds Licensor Licensor Patents Patents
More informationFree Trial Future Generics Database
API Atazanavir Structure O 2 C N H O H N OH N NH O N H N CO2 Brand REYATAZ (BMS : World) Indication Antiviral Originator Ciba-Geigy (Novartis) Developer / Licensee BMS Comments Atazanavir is an azapeptide
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationImportant new concerns or changes to the current ones will be included in updates of Symtuza's RMP.
Summary of Risk Management Plan for Symtuza (D/C/F/TAF) This is a summary of the risk management plan (RMP) for Symtuza. The RMP details important risks of Symtuza, how these risks can be minimised, and
More informationRisk Management Plan Summary
Risk Management Plan Summary EDURANT (rilpivirine) 25 mg film-coated tablet Document Version: 1.0 Document Date: 30.10.2017 Based on EU RMP version 7.0 Marketing authorization holder: Janssen-Cilag AG,
More informationNew Delhi, the 18 th December, 2017 ORDER
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of National Pharmaceutical Pricing Authority
More informationSwiss Summary of the Risk Management Plan (RMP) for
Swiss Summary of the Risk Management Plan (RMP) for GENVOYA (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Version 2.0 (July 2017) Gilead Sciences International Limited Granta Park, Abington
More informationSupplementary information
Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc
More information1. RECOMMENDATIONS OF THE NDAC (NEUROLOGY AND PSYCHIATRY) HELD ON :-
1. RECOMMENDATIONS OF THE NDAC (NEUROLOGY AND PSYCHIATRY) HELD ON 17.12.2011:- The NDAC (Neurology and Psychiatry) deliberated the proposals on 17.12.2011and recommended the following:- AGENDA NO. DRUG
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 15.10.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1 M/S NATCO PHARMA LIMITED HYDERABAD MEDICAL DEVICE S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. GENETIX BIOTECH ASIA PVT. LTD. 22073 APPROVAL
More informationADTC UPDATES ON DRUGS REVIEWED BY THE SMC. The following new drugs have been reviewed by the Scottish Medicines Consortium in July 2013: -
Area Drug and Therapeutics Committee Prescribing Supplement No 72 In this issue Drugs reviewed by the SMC in July 2013 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC The following new drugs have been reviewed
More informationMylan Laboratories Limited F-4 & F-12, Malegaon MIDC, Sinnar Nashik Maharashtra State, India
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationUNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM
Gilead Sciences, Inc. GS-US-337-0115, 25-NOV-2013 A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects
More informationTadalafil And Dapoxetine Tablet
Tadalafil And Dapoxetine Tablet how to use dapoxetine 30mg dapoxetine hcl in india dapoxetine hydrochloride in india where can i get dapoxetine in india dapoxetine 30 mg and sildenafil 50mg where to buy
More informationORDER. Table. Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Rosuvastatin + Clopidogrel Capsule (Crevast CV 20)
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical
More informationState of Industry Readiness for the New Demand Following the New Treatment Guidelines
JOINT MEDICINES PATENT POOL & WHO SATELLITE ON BRIDGING THE NEW TREATMENT GAP: WHAT WILL IT TAKE? State of Industry Readiness f the New Demand Following the New Treatment Guidelines Louis J. Riceberg,
More informationBDS(BACHELOR OF DENTAL SURGERY)
BDS(BACHELOR OF DENTAL SURGERY) INTRODUCTION BDS course focuses on the field of Dental Science. It is a popular undergraduate Dentistry course, which, on completion, leads to a BDS degree and title of
More informationOvercoming the Challenges in Access to TB Drugs for Children
Overcoming the Challenges in Access to TB Drugs for Children Gregory L. Kearns, PharmD, PhD Professor of Pediatrics and Pharmacology, University of Missouri Marion Merrell Dow / Missouri Chair in Pediatric
More informationProduct Monograph. DESCOVY (emtricitabine/tenofovir alafenamide) tablets
INCLUDING PATIENT MEDICATION INFORMATION Pr DESCOVY (emtricitabine/tenofovir alafenamide) tablets 200 mg emtricitabine 10 mg* and 25 mg** tenofovir alafenamide * as 11.2 mg tenofovir alafenamide hemifumarate
More informationInternational Journal of Pharma and Bio Sciences V1(2)2010 A STUDY ON PRESCRIPTION PATTERN AND COST ANALYSIS OF ANTIRETROVIRAL DRUGS.
SANKAR VEINTRAMUTHU 1 *, RUCKMANI KANDASAMY 2, VELAYUTHAM KANNIYAPPAN 1, NITHYANANTH MUNUSAMY 1 1 Department of Pharmaceutics, PSG College of Pharmacy, Coimbatore- 641004. 2 Department of Pharmaceutical
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Excipient with known effect: Darunavir Alvogen 400 mg: Each tablet contains mg sunset yellow FCF (E110).
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Darunavir Alvogen 400 mg, filmomhulde tabletten Darunavir Alvogen 800 mg, filmomhulde tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationHIV prophylaxis for health care providers. Dr. A. K. M. Humayon Kabir Assistant Professor Department of Medicine Dhaka Medical College Hospital
HIV prophylaxis for health care providers. Dr. A. K. M. Humayon Kabir Assistant Professor Department of Medicine Dhaka Medical College Hospital HIV continues to be a major global public health issue, Approximately
More informationCCC Guidance for Pediatric HIV PEP Outside of the Perinatal Period
CCC Guidance for Pediatric HIV PEP Outside of the Perinatal Period There are currently no published guidelines for post-exposure prophylaxis from the CDC/PHS specific to the pediatric population. This
More informationRecommended Comparator Products: Medicines for HIV/AIDS and Related Diseases
Medicines for HIV/AIDS and Related Diseases Comparator products should be purchased from a well-regulated market with a stringent regulatory authority. 1 Invited medicinal products Abacavir, 60 mg, 300
More informationMedicines recommended to prevent and manage the priority diseases at the community and health facility level
s recommended to prevent and manage the priority diseases at the community and health facility level Shamim Qazi Department of Child and Adolescent Health and Development Global Causes of Child Deaths
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 03.09.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1. M/S LUPIN TARAPUR, MAHARASHTRA & WC 2. M/S JPN PHARMA PVT. PALGHAR, MAHARASHTRA WC 3. M/S OPTIMUS DRUGS A.P. WC VACCINE DIVISION S.
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 PREZISTA 400 mg, film-coated tablet B/60 (CIP code: 393 138-3) Applicant: JANSSEN-CILAG darunavir
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology HIV stands for human immunodeficiency virus. If left untreated, HIV can lead to the disease AIDS (acquired immunodeficiency syndrome).
More informationPharmacologic Characteristics and Delivery Options for Integrase Inhibitors
Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious
More informationSummary of the risk management plan (RMP) for Genvoya (elvitegravir/ cobicistat/ emtricitabine / tenofovir alafenamide)
EMA/661227/2015 Summary of the risk management plan (RMP) for Genvoya (elvitegravir/ cobicistat/ emtricitabine / tenofovir alafenamide) This is a summary of the risk management plan (RMP) for Genvoya,
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationList of COPP Skybiotech Life sciences Pvt.Ltd. Factory : Gut No.5, Gevrai Tanda, Paithan Road, Aurangabad.
List of COPP Skybiotech Life sciences Pvt.Ltd. Factory : Gut No.5, Gevrai Tanda, Paithan Road, Aurangabad. S.NO NAME OF PRODUCT COMPOSITION 01 DOLAFREE -50 Tramadol Hydrochloride Tablet 50 mg ( Sublingual
More informationSCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationDevelopment of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir
Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide () Bryan Baugh 1, Erika Van Landuyt 2, Simon Vanveggel 2, Herta
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 November 2010 ISENTRESS 400 mg, film-coated tablet B/60 (CIP code: 383 084-8) Applicant: MSD-CHIBRET raltegravir
More informationIraq NDI Iraq 04-J India 05-AH France Famar Lyon France 05-D UNITED ARAB EMIRATES. Iraqi Biocon Limited Indian 06-AA0-001
nam origmanufacturer nammanufacturer National code Mousel Scientific Iraq NDI Iraq 04-J00-042 Sandoz GmbH Austria for Sandoz GmbH by Sandoz Ilac Sanayi ve India 05-AH0-040 France Famar Lyon France 05-D00-024
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology HIV is a virus that attacks the immune system (the body s natural defences) and weakens it by destroying certain white blood cells
More informationFULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EDURANT safely and effectively. See full prescribing information for EDURANT. EDURANT (rilpivirine)
More informationClinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents
Clinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents Reference: NHS England F03X08 First published: Month Year Prepared by NHS England Specialised
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Enfuvirtide (Fuzeon) Reference Number: CP.PHAR.41 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
More informationLETTERS FOR ISSUE ON
S FOR ISSUE ON 21.06.2016 LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY NO. STATUS 01 M/S. GLOBAL PHARMA HEALTHCARE PVT. LTD., THIRUPORUR 27509 APPROVAL BIOLOGICAL DIVISION NAME OF COMPANY DY.NO. STATUS
More information